Belgian Health Care Knowledge Center has issued update of clinical guidelines for diagnosis and management of pancreatic cancer

In late June 2023, the Belgian Health Care Knowledge Center (KCE) published a report on relevance of transversal budget impact analysis. This type of analysis should be submitted as part of the application to the National Institute for Health and Disability Insurance (INAMI-RIZIV) to obtain reimbursement for implants and invasive medical devices.

In July 2023, the National Institute for Health and Disability Insurance (INAMI-RIZIV) significantly updated the process to obtain reimbursement for health apps. More stakeholders, including the industry, can now submit an application to INAMI-RIZIV for temporary or permanent reimbursement. The new process will come into force on October 1, 2023.

In late June 2023, the National Institute for Health and Disability Insurance (INAMI-RIZIV) decided to extend reimbursement for molecular biology tests by next-generation sequencing (NGS) for one year until June 30, 2024. NGS in oncology and hemato-oncology are temporarily reimbursed as a pilot under a specific agreement (Convention) with INAMI-RIZIV from 2019.

On July 1, 2023, the National Institute for Health and Disability Insurance (INAMI-RIZIV) updated the conditions of reimbursement for continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM, commonly called flash glucose monitoring, FGM). Full coverage by health insurance became available to more patient categories.

In June 2023, the Belgian Health Care Knowledge Center (KCE) published Health Services Research concerning the performance of the Belgian healthcare system. KCE regularly conducts such "check-ups" of the healthcare system in collaboration with Sciensano, the National Institute for Health and Disability Insurance (INAMI/RIZIV), and the FPS Public Health. The conceptual framework and the list of performance indicators were revised and updated.